nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.04.2012 | Original article

Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines

verfasst von: D. Schilling, C. Bayer, K. Emmerich, M. Molls, P. Vaupel, R.M. Huber, Prof. Dr. G. Multhoff

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

High levels of hypoxia inducible factor (HIF)-1α in tumors are reported to be associated with tumor progression and resistance to therapy. To examine the impact of HIF-1α on radioresistance under normoxia, the sensitivity towards irradiation was measured in human tumor cell lines that differ significantly in their basal HIF-1α levels.

Material and methods

HIF-1α levels were quantified in lysates of H1339, EPLC-272H, A549, SAS, XF354, FaDu, BHY, and CX- tumor cell lines by ELISA. Protein levels of HIF-1α, HIF-2α, carbonic anhydrase IX (CA IX), and GAPDH were assessed by Western blot analysis. Knock-down experiments were performed using HIF-1α siRNA. Clonogenic survival after irradiation was determined by the colony forming assay.

Results

According to their basal HIF-1α status, the tumor cell lines were divided into low (SAS, XF354, FaDu, A549, CX-), intermediate (EPLC-272H, BHY), and high (H1339) HIF-1α expressors. The functionality of the high basal HIF-1α expression in H1339 cells was proven by reduced CA IX expression after knocking-down HIF-1α. Linear regression analysis revealed no correlation between basal HIF-1α levels and the survival fraction at either 2 or 4 Gy in all tumor cell lines investigated.

Conclusion

Our data suggest that basal HIF-1α levels in human tumor cell lines do not predict their radiosensitivity under normoxia.

Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916PubMed

Akakura N, Kobayashi M, Horiuchi I et al (2001) Constitutive expression of hypoxia-inducible factor-1a renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61:6548–6554PubMed

Appelhoff RJ, Tian YM, Raval RR et al (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279:38458–38465PubMedCrossRef

Aprelikova O, Pandolfi S, Tackett S et al (2009) Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 69:616–624PubMedCrossRef

Berra E, Benizri E, Ginouves A et al (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22:4082–4090PubMedCrossRef

Carmeliet P, Dor Y, Herbert JM et al (1998) Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485–490PubMedCrossRef

Chan DA, Sutphin PD, Denko NC, Giaccia AJ (2002) Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 277:40112–40117PubMedCrossRef

Dang DT, Chen F, Gardner LB et al (2006) Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 66:1684–936PubMedCrossRef

Dellas K, Bache M, Pigorsch SU et al (2008) Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 184:169–174PubMedCrossRef

10.

Dewhirst MW, Cao Y, Li CY, Moeller B (2007) Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 83:249–255PubMedCrossRef

11.

Fu XS, Choi E, Bubley GJ, Balk SP (2005) Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 63:215–221PubMedCrossRef

12.

Greijer AE, Wall E van der (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57:1009–1014PubMedCrossRef

13.

Jung SY, Song HS, Park SY (2011) Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression. Int J Oncol 38:571–576PubMed

14.

Kappler M, Taubert H, Holzhausen HJ et al (2008) Immunohistochemical detection of HIF-1a and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol 184:393–399PubMedCrossRef

15.

Kessler J, Hahnel A, Wichmann H et al (2010) HIF-1a inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer 10:605PubMedCrossRef

16.

Kim WY, Oh SH, Woo JK et al (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1a. Cancer Res 69:1624–1632PubMedCrossRef

17.

Koukourakis MI, Giatromanolaki A, Sivridis E et al (2002) Hypoxia-inducible factor (HIF1 α and HIF2 α), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192–202PubMedCrossRef

18.

Krieg M, Haas R, Brauch H et al (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435–5443PubMedCrossRef

19.

Liu J, Zhang J, Wang X et al (2010) HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 316:1985–1993PubMedCrossRef

20.

Maftei CA, Bayer C, Shi K et al (2011) Quantitative assessment of hypoxia subtypes in microcirculatory supply units of malignant tumors using (immuno-)fluorescence techniques. Strahlenther Onkol 187:260–266PubMedCrossRef

21.

Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99–110PubMedCrossRef

22.

Multhoff G, Botzler C, Jennen L et al (1997) Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol 158:4341–4350PubMed

23.

Nordsmark M, Eriksen JG, Gebski V et al (2007) Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83:389–397PubMedCrossRef

24.

Paltoglou SM, Roberts BJ (2005) Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1alpha and its oxygen-regulated transactivation domains at high cell density. Oncogene 24:3830–3835PubMedCrossRef

25.

Sasabe E, Tatemoto Y, Li D et al (2005) Mechanism of HIF-1a-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96:394–402PubMedCrossRef

26.

Schilling D, Gehrmann M, Steinem C et al (2009) Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J 23:2467–2477PubMedCrossRef

27.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732PubMedCrossRef

28.

Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625–634PubMedCrossRef

29.

Staab A, Fleischer M, Loeffler J et al (2011) Small interfering RNA targeting HIF-1a reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 187:252–259PubMedCrossRef

30.

Strofer M, Jelkmann W, Depping R (2011) Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlenther Onkol 187:393–400PubMedCrossRef

31.

Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239PubMedCrossRef

32.

Vaupel P, Mayer A, Höckel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381:335–354PubMedCrossRef

33.

Zips D, Boke S, Kroeber T et al (2011) Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control. Strahlenther Onkol 187:306–310PubMedCrossRef

Titel: Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines
verfasst von: D. Schilling
C. Bayer
K. Emmerich
M. Molls
P. Vaupel
R.M. Huber
Prof. Dr. G. Multhoff
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-011-0051-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines

Abstract

Background and purpose

Material and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and purpose

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Lebensqualität nach prophylaktischer Ganzhirnbestrahlung beim lokal fortgeschrittenen, nicht-kleinzelligen Bronchialkarzinom

Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients

Mitteilungen

Pitfalls in radiation oncology

Gemcitabin-basierte Strahlenchemotherapie beim lokal fortgeschrittenen Pankreaskarzinom – eine Metaanalyse

Stereotactic LINAC radiosurgery for the treatment of brainstem cavernomas

Neu im Fachgebiet Onkologie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Onkologie